Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) (IPPoMS)
Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
A PHASE1/PHASE2 clinical study on Primary Progressive Multiple Sclerosis, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 10 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Sep 2018 — Apr 2019 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .